{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:35:52Z","timestamp":1761863752673},"reference-count":10,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.8214-16","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T18:10:24Z","timestamp":1507659024000},"page":"3211-3213","source":"Crossref","is-referenced-by-count":6,"title":["Crizotinib-induced Rectal Perforation with Abscess"],"prefix":"10.2169","volume":"56","author":[{"given":"Asako","family":"Yanagisawa","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Funabashi Municipal Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Hayama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Funabashi Municipal Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Funabashi Municipal Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Funabashi Municipal Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Oncology Medicine, Funabashi Municipal Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukeyuki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Funabashi Municipal Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tabeta","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Funabashi Municipal Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385-2394, 2013."},{"key":"2","unstructured":"2. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371: 2167-2177, 2014."},{"key":"3","first-page":"112","volume":"88","author":"T Koizumi","year":"2015","unstructured":"3. Koizumi T, Fukushima T, Tatai T, et al. Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer. Lung Cancer 88: 112-113, 2015.","journal-title":"Lung Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"4","first-page":"349","volume":"88","author":"Y Yoneshima","year":"2015","unstructured":"4. Yoneshima Y, Okamoto I, Takano T, et al. Successful treatment with alectinib after crizotinib-induced esophageal ulceration. Lung Cancer 88: 349-351, 2015.","journal-title":"Lung Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"5","unstructured":"5. Kim MS, Kook EH, Ahn SH, et al. Gastrointestinal metastasis of lung cancer with special emphasis on a long-term survivor after operation. J Cancer Res Clin Oncol 135: 297-301, 2009."},{"key":"6","first-page":"76","volume":"99","author":"F Gass-J\u00e9gu","year":"2016","unstructured":"6. Gass-J\u00e9gu F, Gschwend A, Gairard-Dory AC, et al. Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review. Lung Cancer 99: 76-78, 2016.","journal-title":"Lung Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"7","unstructured":"7. Cheon YH, Kim MJ, Kang MG, et al. Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer. Yonsei Med J 52: 695-698, 2011."},{"key":"8","unstructured":"8. Kurata Y, Miyauchi N, Suno M, Ito T, Sendo T, Kiura K. Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer. J Pharm Health Care Sci 1: 8, 2015."},{"key":"9","unstructured":"9. Fukuizumi A, Miyanaga A, Seike M, et al. Effective crizotinib schedule for an elderly patient with ALK-rearranged non-small-cell lung cancer: a case report. BMC Res Notes 8: 165, 2015."},{"key":"10","unstructured":"10. Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34: 661-668, 2016."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/23\/56_8214-16\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T23:35:29Z","timestamp":1512171329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/23\/56_8214-16\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":10,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8214-16","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}